GlassScriptPhysician profile
Kara R Shay
NPI 1578508271
$1,802.20
in general payments reported to CMS, 2019-2025
22 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $77.24 · 2021: $245 · 2022: $129 · 2023: $409 · 2024: $323 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $494.21 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Teleflex LLC | $332.18 | 2023-2025 | Urolift, Barrigel |
| E.R. Squibb & Sons, L.L.C. | $268.85 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $130.80 | 2019-2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $97.76 | 2019-2022 | |
| Novo Nordisk INC | $94.49 | 2021-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $62.94 | 2022-2025 | |
| Amgen INC. | $39.47 | 2021-2022 | |
| Glaxosmithkline, LLC. | $32.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $26.42 | 2019 | |
| Gilead Sciences, INC. | $25.30 | 2024 | |
| Merck Sharp & Dohme LLC | $22.65 | 2019 | |
| Astellas Pharma US INC | $22.16 | 2024 | Veozah |
| Biogen, INC. | $20.50 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.44 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.24 | 2021 | |
| Amarin Pharma, INC. | $17.77 | 2019 | |
| Dexcom, INC. | $17.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.16 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.73 | 2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $13.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Shay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.